Molecular Formula | C21H25N5O8S2 |
Molar Mass | 539.58 |
Density | 1.63±0.1 g/cm3(Predicted) |
Boling Point | 655.5°C at 760 mmHg |
Flash Point | 350.2°C |
Vapor Presure | 7.13E-19mmHg at 25°C |
pKa | pKa 2.7 (Uncertain) |
Storage Condition | 2-8°C |
Refractive Index | 1.569 |
Use | Semi-synthetic broad-spectrum penicillin, Pseudomonas aeruginosa, Proteus, Escherichia coli and other strong role |
introduction | mezlocillin is a broad-spectrum penicillin antibiotic. It is effective for Gram-negative and some Gram-positive bacteria. Unlike most other broad-spectrum penicillins, it is excreted by the liver and is therefore useful for infections of the biliary tract, such as ascending cholangitis. |
Penicillin anti-infective drugs | Mezlocillin is currently commonly used clinical anti-infective drugs of benzimidazole penicillin, belonging to the third generation of semi-synthetic β-lactam antibiotics, also known as sulbenzimidazole penicillin, sulfamethoxazole ampicillin sodium, sulfamethoxazole penicillin sodium, sulfamethoxazole penicillin sodium, mezlocillin sodium, norxelin, Tianlin, it was successfully developed by Bayer Pharmaceuticals in Germany for the first time. It is effective against Gram-positive bacteria, Gram-negative bacteria and anaerobic bacteria. Its antibacterial spectrum, antibacterial power and indications are similar to fubencillin and azlocillin. The combination of bacterial penicillin binding proteins (PBPs) interferes with the synthesis of bacterial cell walls and plays an antibacterial effect. Because this drug forms multi-site binding with PBPs necessary for the survival of Pseudomonas aeruginosa, and it has a penetrating effect on the bacterial cell membrane, making it have a strong antibacterial effect on Pseudomonas (such as Pseudomonas aeruginosa). It has inhibitory effect on Pseudomonas aeruginosa, Escherichia coli, Pneumonia, Proteus, Enterobacter, Citrobacter, Serratia, Acinetobacter and Gram-positive cocci sensitive to penicillin, and has bactericidal effect in large doses. The antibacterial activity against Escherichia coli, Enterobacter, Pneumonia, Citrobacter, Serratia and Acinetobacter is stronger than that of carbenicillin, ampicillin, amoxicillin and ampicillin. The antibacterial activity against indole-positive Proteus, Pseudomonas aeruginosa and Streptococcus faecalis is stronger than that of amoxicillin and sulbenicillin. At the same time, it also has a better effect on most anaerobic bacteria such as Bacillus fragilis. The effect on G + bacteria is similar to that of carbenicillin. However, it is unstable to β-lactamase and has no effect on β-lactamase-producing Staphylococcus aureus and β-lactamase-producing Enterobacter. The gastrointestinal tract is not absorbed. After intravenous administration of 1~5g, the blood drug concentration can reach 56mg/L and 383.5mg/L after 5min. PBP is 27%. After absorption, it is widely distributed in the body. This product can penetrate the heart valve, papillary muscle and prostate tissue. It has the highest concentration in pleural effusion and bile, but it is not easy to penetrate into bronchial secretions. After conventional dose administration, the concentration in the secretions is only 1~5mg/L. Most of them are excreted from the urine in their original form, and a small amount is inactivated in the body. mezlocillin is mainly used for infections of respiratory system, urinary system, digestive system, gynecology and reproductive organs caused by sensitive strains of gram-negative bacilli such as Escherichia coli, Pseudomonas aeruginosa, Enterobacter and Proteus. It has good curative effect on sepsis, purulent meningitis, peritonitis, osteomyelitis, skin and soft tissue infection, ophthalmology and otolaryngology infection. |
Sulbactam combined with mezlocillin | Sulbactam is a synthetic irreversible competitive β-lactamase inhibitor with weak antibacterial activity and slightly stronger than clavulanic acid. It only has bactericidal effect on Neisseria, Neisseria gonorrhoeae and Acinetobacter when used alone. It has a strong inhibitory effect on the vast majority of β-lactamases produced by Gram-positive and Gram-negative bacteria, but is ineffective against metallo-β-lactamases. Sulbactam combined with penicillins or cephalosporins can generally have obvious synergistic effects, which greatly improves the antibacterial activity of the first two and expands the antibacterial spectrum. Combined application with ampicillin can reduce the minimum inhibitory concentration of Staphylococcus, catarrhal, Neisseria, Haemophilus, Escherichia coli, Klebsiella, some Proteus and Bacteroides to ampicillin and increase the efficiency, and can make the enzyme-producing strains sensitive to ampicillin. Clinically suitable for the treatment of upper and lower respiratory tract infections caused by sensitive bacteria, upper and lower urinary tract infections, peritonitis, cholecystitis, cholangitis, and other intra-abdominal infections, sepsis, meningitis, skin and soft tissue infections, bones And joint infections, pelvic inflammatory disease, endometritis, gonorrhea and other genital infections. Mezlocillin/sulbactam compound preparation enhances the effect of mezlocillin on many enzyme-producing gram-positive bacteria, negative bacteria and anaerobic bacteria by inhibiting β-lactamase, not only improves the broad-spectrum antibacterial activity of Pseudomonas aeruginosa, but also broadens the antibacterial spectrum including β-lactamase production, which can effectively treat the infection of enzyme-producing drug-resistant strains. |
use | semi-synthetic broad-spectrum penicillin has strong effect on Pseudomonas aeruginosa, Proteus, Escherichia coli, etc |